Who is sponsoring NCT00930033?

NCT00930033 is sponsored by Assistance Publique - Hôpitaux de Paris.

What drugs are being tested in NCT00930033?

Interventions in NCT00930033: Nephrectomy, Sunitinib alone.

What condition does NCT00930033 study?

NCT00930033 studies Metastatic Renal Cell Carcinoma.

Is NCT00930033 still recruiting?

NCT00930033 is currently completed. Last updated 5 September 2025.

Last reviewed 2025-09-05 · How we verify

NCT00930033: CARMENA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Trial to Assess the Importance of Nephrectomy

Completed Phase 3 Last updated 5 September 2025

What this trial tests

Phase 3 trial testing Nephrectomy in Metastatic Renal Cell Carcinoma in 452 participants. Completed in 22 October 2018.

Timeline

9 September 2009

Primary endpoint
22 October 2018

22 October 2018

Quick facts

Lead sponsor	Assistance Publique - Hôpitaux de Paris
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	452
Start date	9 September 2009
Primary completion	22 October 2018
Estimated completion	22 October 2018
Sites	1 location across France

Drugs / interventions tested

Nephrectomy
Sunitinib alone — full drug profile →

Conditions studied

Metastatic Renal Cell Carcinoma — all drugs for Metastatic Renal Cell Carcinoma →

Sponsor

Assistance Publique - Hôpitaux de Paris — full company profile →

Who can join

18 and older, any sex, with Metastatic Renal Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study compare the standard treatment with nephrectomy + sunitinib to treatment with sunitinib alone without nephrectomy. This study will be the first trial on this competitive context

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.
Méjean A, Ravaud A, Thezenas S, Colas S, et al · · 2018 · cited 620× · PMID 29860937 · DOI 10.1056/nejmoa1803675
Renal cell carcinoma.
Jonasch E, Gao J, Rathmell WK. · · 2014 · cited 518× · PMID 25385470 · DOI 10.1136/bmj.g4797
Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
Hanna N, Sun M, Meyer CP, Nguyen PL, et al · · 2016 · cited 141× · PMID 27325852 · DOI 10.1200/jco.2016.66.7931
Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era.
Conti SL, Thomas IC, Hagedorn JC, Chung BI, et al · · 2014 · cited 92× · PMID 24135850 · DOI 10.1002/ijc.28553
The Changing Therapeutic Landscape of Metastatic Renal Cancer.
Angulo JC, Shapiro O. · · 2019 · cited 49× · PMID 31443471 · DOI 10.3390/cancers11091227
Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach.
Shinder BM, Rhee K, Farrell D, Farber NJ, et al · · 2017 · cited 49× · PMID 28620578 · DOI 10.3389/fonc.2017.00107
Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis.
Tsao CK, Small AC, Kates M, Moshier EL, et al · · 2013 · cited 46× · PMID 23223962 · DOI 10.1007/s00345-012-1001-3
Update on targeted therapies for clear cell renal cell carcinoma.
Singer EA, Gupta GN, Srinivasan R. · · 2011 · cited 46× · PMID 21330923 · DOI 10.1097/cco.0b013e32834479c0

Verify or expand the search:

Other trials of Nephrectomy

Trials testing the same drug.

NCT07226544 — Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer · Phase 2 · not yet recruiting
NCT07516366 — Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell R · Phase 2 · not yet recruiting
NCT06401330 — A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) · Phase 3 · recruiting
NCT04402749 — The Incidence of Pulmonary Embolism During Nephrectomy · completed
NCT04326517 — Factors Associated To Intensive Care Admission And Mortality In Patients With Emphysematous Pyelonephritis · unknown

Other recruiting trials for Metastatic Renal Cell Carcinoma

Currently open trials in the same condition.

NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
NCT07123090 — A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma · Phase 2 · recruiting
NCT06391099 — Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic · NA · recruiting
NCT06500455 — Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to · Phase 3 · recruiting

Other Assistance Publique - Hôpitaux de Paris trials

Trials by the same sponsor.

NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00930033 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00930033.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing